Of the tracked stories, 3 of 3 also mention Dole, the most common co-covered peer. The clearest coverage concentration is earnings: 2 of 3 stories, with the rest divided among 1 other category. We currently track 3 Cross-Sector stories that mention LifeStance Health Group, all published on February 25, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about LifeStance Health Group
Of the tracked stories, 3 of 3 also mention Dole, the most common co-covered peer. The clearest coverage concentration is earnings: 2 of 3 stories, with the rest divided among 1 other category. We currently track 3 Cross-Sector stories that mention LifeStance Health Group, all published on February 25, 2026. Each carries 2 original sources on average.
Stories tracked
3
Sources per story
2
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering LifeStance Health Group. Shared-story counts are live from our verified record — not editorial picks.
LifeStance Health Group and Dole have released their fourth-quarter results, providing a roadmap for 2026 that highlights divergent paths in the healthcare and consumer staples sectors. While LifeStance focuses on scaling its mental health platform, Dole navigates a complex global supply chain to maintain its fresh produce leadership.
Dole and LifeStance Health Group both released Q4 results and forward-looking FY26 guidance, highlighting a period of stabilization and strategic expansion. While Dole navigates mixed performance in the fresh produce sector, LifeStance continues to scale its mental health footprint, reflecting broader shifts in consumer spending toward essential wellness.
LifeStance Health Group reported its fourth-quarter results for 2025, concurrently issuing a strategic financial outlook for fiscal year 2026. The company is pivoting from aggressive footprint expansion toward margin optimization and clinician retention as it targets long-term profitability.